Usefulness of HE4 protein in differentiation of pelvic masses in woman.

Autor: Brenk A; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland., Bodzek P; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland., Baliś M; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland., Barbachowska A; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland., Janosz I; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland., Olejek A; Department of Gynaecology, Obstetrics and Oncological Gynaecology, Medical University of Silesia, Poland.
Jazyk: angličtina
Zdroj: Przeglad menopauzalny = Menopause review [Prz Menopauzalny] 2019 Apr; Vol. 18 (1), pp. 27-32. Date of Electronic Publication: 2019 Apr 09.
DOI: 10.5114/pm.2019.84154
Abstrakt: Introduction: HE4 protein (human epididymis protein-4), which is the fourth subfraction of human epithelial protein, is a glycoprotein widely used as a tumor marker in ovarian cancer. If was first discovered in the epididymal epithelium and recognized as a protease inhibitor contributing to sperm maturation. The plasma HE4 concentration may also be increased in gynecological pathologies other than ovarian cancer.
Material and Methods: The study was conducted between 2016 and 2017 among patients hospitalized in the Academic Department of Gynaecology. A total of 191 women were examined. Depending on the type of pathology which was the reason for hospitalization, 4 groups of patients were identified in the study. The first of these included 30 patients with ovarian cancer, the second 33 patients with benign ovarian lesion, the third 50 patients with endometrial cancer, and the fourth 28 patients with leiomyomas.
Results: The highest concentration of HE4 protein was found in women with ovarian cancer, and it was statistically significantly higher compared to all other groups. Lower HE4 protein concentration than in women with ovarian cancer was reported in women with endometrial cancer, but it was statistically significantly higher compared to patients with uterine fibroids.
Conclusions: This marker may have significant clinical value in the differentiation of benign ovarian pathology from ovarian cancer. The study confirms the validity of using HE4 results in the assessment of potential malignancy of ovarian and endometrial lesions.
Competing Interests: The authors report no conflict of interest.
Databáze: MEDLINE
Externí odkaz: